Site Sponsors
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Strem Chemicals - Nanomaterials for R&D
Posted in | Nanobusiness

NanoViricides Completes Number of Financing Activities

Published on October 5, 2009 at 7:37 AM

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has completed a number of financing activities.

The Company has successfully raised more than $4.3M. This raise involved issuance of restricted shares and warrant conversions in private placements to certain accredited investors. The Company is filing a Form 8-K disclosure with the SEC summarizing these activities on October 5, 2009.

“With sufficient working capital to last us through December 31, 2010,” said Eugene Seymour, MD, MPH, CEO of the Company, “we are now ready to engage full steam with our high priority drug development activities.”

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit